TABLE 2

Kaplan-Meier estimates for efficacy outcomes following pyronaridine-artesunate treatment of P. falciparum malaria at three study sites in western Cambodia

OutcomeValue for groupb
Pursat (n = 60)Pailin (n = 55)Battambang (n = 8)
Day 42 PCR-adjusted ACPR (%) (95% CI)89.8 (78.8, 95.3)84.0 (70.6, 91.7)100 (100, 100)
Day 42 crude ACPR (%) (95% CI)89.8 (78.8, 95.3)82.1 (68.4, 90.2)100 (100, 100)
Day 28 PCR-adjusted ACPR (%) (95% CI)a93.2 (82.9, 97.4)88.1 (75.3, 94.5)100 (100, 100)
% of patients with parasite clearance (95% CI) on day:
    110.0 (4.6, 20.9)5.5 (1.8, 16.0)12.5 (1.9, 61.3)
    240.0 (28.9, 53.5)29.1 (18.9, 43.0)37.5 (13.9, 77.1)
    386.7 (76.8, 93.8)56.4 (43.9, 69.6)75.0 (44.2, 96.3)
Median parasite clearance time (days) (95% CI)3.0 (2.0, 3.0)3.0 (3.0, NA)3.0 (1.0, NA)
% of patients with fever clearance (95% CI) on day:
    185.0 (74.9, 92.6)36.4 (25.2, 50.5)50.0 (22.5, 84.8)
    2100 (100, 100)74.5 (62.6, 85.1)100 (100, 100)
    3100 (100, 100)98.2 (91.5, 99.9)100 (100, 100)
Median fever clearance time (days) (95% CI)1.0 (1.0, 1.0)2.0 (1.0, 2.0)1.5 (1.0, NA)
  • a Results for the day 28 crude ACPR were the same as those for the day 28 PCR-adjusted ACPR.

  • b NA, not applicable.